Back to Search Start Over

U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Pegfilgrastim for Review

Source :
PR Newswire. February 16, 2017
Publication Year :
2017

Abstract

Second Successful BLA Filing of the Partnership in the U.S. HERTFORDSHIRE, England, PITTSBURGH and®BENGALURU, India, Feb. 16, 2017 /PRNewswire/ --®Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, [...]

Details

Language :
English
Database :
Gale General OneFile
Journal :
PR Newswire
Publication Type :
News
Accession number :
edsgcl.482244019